Comparable stake leader
MAVERICK CAPITAL LTD
SEC ownership of ROCKET PHARMACEUTICALS, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001281895.
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
3/50
Latest evidence
11 Sep 2026
- Public ticker
- RCKT on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
MAVERICK CAPITAL LTD
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
3 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
MAVERICK CAPITAL LTD
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
11 Sep 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001281895
- Issuer location
- New York, NY
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ROCKET PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MAVERICK CAPITAL LTD
Disclosed value leader
RTW INVESTMENTS, LP
Comparable rows
3/50
Latest evidence
11 Sep 2026
13F
13D/G
3/4/5
Lead comparable stake: 2.3%
47 rows are not safely comparable across share classes.
13D/G row: MAVERICK CAPITAL LTD
Showing 1-8 of 50 holder rows.
Quick read
MAVERICK CAPITAL LTD leads the comparable SEC ownership view at 2.3%.
3 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MAVERICK CAPITAL LTD's linked filing trail.
Comparable ownership
Top 3
MAVERICK CAPITAL LTD
2.3%
VANGUARD PORTFOLIO MANAGEMENT LLC
1.3%
WELLINGTON MANAGEMENT GROUP LLP
0.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MAVERICK CAPITAL LTD |
13F
13D/G
Company
|
2.3%
Reported 13D/G
· 31 Dec 2025
|
$13,419,953
3,923,963 shares
|
— | 30 Jun 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Portfolio Management
|
1.3%
Reported 13D/G
· 30 Sep 2026
|
$19,870,313
5,810,033 shares
|
— | 30 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
Company
|
0.9%
Reported 13D/G
· 30 May 2025
|
$7,895,181
1,004,476 shares
|
-$48,317,346 | 30 May 2025 |
| RTW INVESTMENTS, LP |
3/4/5
13F
Director, Other*, 10%+ Owner · Company
|
—
mixed-class rows
|
$100,686,510
21,763,079 shares
mixed-class rows
|
— | 19 Sep 2025 |
| Roderick Wong |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$62,482,819
18,342,916 shares
mixed-class rows
|
— | 18 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$33,939,951
9,923,962 shares
|
— | 30 Jun 2026 |
| CITIGROUP INC |
13F
Company
|
—
denominator unverified
|
$16,640,184
4,865,551 shares
|
— | 30 Jun 2026 |
| MARSHALL WACE, LLP |
13F
Company
|
—
denominator unverified
|
$13,780,075
4,029,262 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$829,604.
Buys
$34,400
Insiders: 1
Sells
$864,004
Insiders: 6
Net
-$829,604
Shares: -248,044
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 10,000
Shares: 258,044
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 125,977 | $0 | $432,467 | -$432,467 |
| 3-6 | 0 | 83,733 | $0 | $275,035 | -$275,035 |
| 6-9 | 0 | 36,781 | $0 | $122,040 | -$122,040 |
| 9-12 | 10,000 | 11,553 | $34,400 | $34,463 | -$62.6 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to ROCKET PHARMACEUTICALS, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
RTW INVESTMENTS, LP
Net 12M change
-$829.6K
Full value: -$829,604 · USD · 12-month changeLatest report
11 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | Director, Other*, 10%+ Owner | $100,686,510 | Mixed | 19 Sep 2025 | ||
| Roderick Wong | Director, 10%+ Owner | $62,482,819 | Mixed | 18 Jun 2026 | ||
| Gaurav Shah | Ceo | $8,621,586 | -$285,667 | -3.2% | Mixed | 18 Aug 2026 |
| Kinnari Patel | President, Head of R&D and Chief Operating Officer | $6,417,297 | Mixed | 20 May 2025 | ||
| Martin Louis Wilson | General Counsel | $4,061,674 | -$334,607 | -7.6% | Mixed | 11 Sep 2026 |
| Jonathan David Schwartz | Chief Science & Gene Therapy Officer | $2,692,124 | -$7,592 | -0.28% | Mixed | 18 Nov 2025 |
| Gotham Makker | Director | $2,545,450 | Mixed | 18 Jun 2025 | ||
| Aaron Ondrey | Chief Financial Officer | $2,394,410 | Mixed | 03 Jul 2025 | ||
| Christopher James Stevens | Chief Operating Officer | $1,769,738 | -$128,266 | -6.8% | Filing P/S | 11 Aug 2026 |
| Mark Andrew White | General Manager, Commercial Affairs | $1,560,177 | Mixed | 31 Oct 2024 | ||
| Syed Ali-Aamir Rizvi | Chief Medical Officer | $1,549,921 | Mixed | 11 Feb 2026 | ||
| David P. Southwell | Director | $1,086,349 | Mixed | 03 Aug 2026 | ||
| Carlos Garcia-Parada | Chief Financial Officer | $1,068,080 | Mixed | 14 Feb 2022 | ||
| Sarbani Chaudhuri | Chief Commercial & Medical Affairs Officer | $919,568 | -$84,189 | -8.4% | Filing P/S | 11 Aug 2026 |
| John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | $720,593 | -$23,683 | -3.2% | Mixed | 26 May 2026 |
| Mikael Dolsten | Director | $575,234 | Mixed | 18 Jun 2026 | ||
| Piratip Pratumsuwan | Director | $411,061 | Mixed | 18 Jun 2025 | ||
| Keith Woods | Director | $360,118 | Mixed | 13 Jun 2024 | ||
| Peter Fong | Director | $260,670 | Mixed | 18 Jun 2026 | ||
| Carsten Boess | Director | $180,846 | Mixed | 18 Jun 2026 |
Recent insider transactions for ROCKET PHARMACEUTICALS, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Martin Louis Wilson | RCKT | Common Stock | Sale | -11.2% | -$256,464 | $3.40 | -75,364 | 598,489 | 11 Sep 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.09% | -$2,133 | $3.38 | -631 | 673,853 | 18 Aug 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.22% | -$7,753 | $3.38 | -2,293 | 1,056,594 | 18 Aug 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.27% | -$9,592 | $3.38 | -2,837 | 1,058,887 | 13 Aug 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.52% | -$11,810 | $3.38 | -3,493 | 674,484 | 13 Aug 2026 | Direct |
| Christopher James Stevens | RCKT | Common Stock | Sale | -6.76% | -$128,266 | $3.50 | -36,658 | 505,784 | 11 Aug 2026 | Direct |
| Sarbani Chaudhuri | RCKT | Common Stock | Sale | -1.76% | -$16,449 | $3.50 | -4,701 | 262,809 | 11 Aug 2026 | Direct |
| Christopher James Stevens | RCKT | Common Stock | Award | 15.6% | 73,313 | 542,442 | 03 Aug 2026 | Direct | ||
| Christopher James Stevens | RCKT | Stock Option (Right to Buy) | Award | 101,428 | 101,428 | 03 Aug 2026 | Direct | |||
| David P. Southwell | RCKT | Common Stock | Other | 275.1% | 150,000 | 204,522 | 03 Aug 2026 | Direct | ||
| Roderick Wong | RCKT | Common Stock | Award | 58.4% | 27,832 | 75,499 | 18 Jun 2026 | Direct | ||
| Roderick Wong | RCKT | Stock Option (Right to Buy) | Award | 78,960 | 78,960 | 18 Jun 2026 | Direct | |||
| Peter Fong | RCKT | Common Stock | Award | 42.9% | 22,862 | 76,195 | 18 Jun 2026 | Direct | ||
| Peter Fong | RCKT | Stock Option (Right to Buy) | Award | 64,860 | 64,860 | 18 Jun 2026 | Direct | |||
| Mikael Dolsten | RCKT | Common Stock | Award | 51.7% | 22,862 | 67,082 | 18 Jun 2026 | Direct | ||
| Mikael Dolsten | RCKT | Stock Option (Right to Buy) | Award | 64,860 | 64,860 | 18 Jun 2026 | Direct | |||
| Fady Ibraham Malik | RCKT | Common Stock | Award | 76.2% | 22,862 | 52,862 | 18 Jun 2026 | Direct | ||
| Fady Ibraham Malik | RCKT | Stock Option (Right to Buy) | Award | 64,860 | 64,860 | 18 Jun 2026 | Direct | |||
| David P. Southwell | RCKT | Common Stock | Award | 72.2% | 22,862 | 54,522 | 18 Jun 2026 | Direct | ||
| David P. Southwell | RCKT | Stock Option (Right to Buy) | Award | 64,860 | 64,860 | 18 Jun 2026 | Direct | |||
| Carsten Boess | RCKT | Common Stock | Award | 76.2% | 22,862 | 52,862 | 18 Jun 2026 | Direct | ||
| Carsten Boess | RCKT | Stock Option (Right to Buy) | Award | 64,860 | 64,860 | 18 Jun 2026 | Direct | |||
| John Militello | RCKT | Stock Option (Right to Buy) | Award | 116,562 | 51,509 | 26 May 2026 | Direct | |||
| John Militello | RCKT | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -238,256 | 0 | 26 May 2026 | Direct | ||
| Gaurav Shah | RCKT | Common Stock | Sale | -4.98% | -$171,841 | $3.09 | -55,684 | 1,061,724 | 21 May 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Options Exercise | 7.35% | 76,490 | 1,117,408 | 21 May 2026 | Direct | ||
| Gaurav Shah | RCKT | Stock Option (Right to Buy) | Options Exercise | -100% | -76,490 | 0 | 21 May 2026 | Direct | ||
| Gaurav Shah | RCKT | Common Stock | Sale | -0.23% | -$7,261 | $3.01 | -2,409 | 1,040,918 | 19 May 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.1% | -$1,995 | $3.01 | -662 | 677,977 | 19 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.43% | -$1,157 | $3.01 | -384 | 89,780 | 19 May 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.49% | -$12,120 | $3.61 | -3,361 | 678,639 | 13 May 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.26% | -$9,837 | $3.61 | -2,728 | 1,043,327 | 13 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.94% | -$3,083 | $3.61 | -855 | 90,164 | 13 May 2026 | Direct |
| Sarbani Chaudhuri | RCKT | Common Stock | Sale | -6.19% | -$67,741 | $3.84 | -17,650 | 267,510 | 07 May 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.26% | -$3,862 | $3.34 | -1,157 | 91,019 | 18 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.57% | -$19,995 | $3.34 | -5,990 | 1,046,055 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.2% | -$4,593 | $3.34 | -1,376 | 682,000 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -1.76% | -$40,582 | $3.31 | -12,253 | 683,376 | 13 Feb 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -3.89% | -$12,341 | $3.31 | -3,726 | 92,176 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -1.15% | -$40,668 | $3.31 | -12,279 | 1,052,045 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Award | 36.8% | 286,028 | 1,064,324 | 11 Feb 2026 | Direct | ||
| Gaurav Shah | RCKT | Stock Option (Right to Buy) | Award | 870,648 | 870,648 | 11 Feb 2026 | Direct | |||
| John Militello | RCKT | Common Stock | Award | 45.5% | 29,982 | 95,902 | 11 Feb 2026 | Direct | ||
| John Militello | RCKT | Stock Option (Right to Buy) | Award | 45,018 | 45,018 | 11 Feb 2026 | Direct | |||
| Martin Louis Wilson | RCKT | Common Stock | Award | 81.2% | 311,813 | 695,629 | 11 Feb 2026 | Direct | ||
| Martin Louis Wilson | RCKT | Stock Option (Right to Buy) | Award | 468,187 | 468,187 | 11 Feb 2026 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 17.9% | 61,963 | 407,874 | 11 Feb 2026 | Direct | ||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Christopher James Stevens | RCKT | Common Stock | Award | 15.2% | 61,963 | 469,129 | 11 Feb 2026 | Direct | ||
| Christopher James Stevens | RCKT | Stock Option (Right to Buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct |
* marks a reported price that did not pass the local price check.